CCNDBP1 and myeloid sarcoma: Additionally, the changes in GCIP and RNFL measures can be more observable for MS patients with shorter duration of disease, which have more intact neuroaxonal substrate relative to MS patients with longer duration of disease and pre‐existing injury to afferent visual pathways.